{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:48:15Z","timestamp":1787777295273,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.leukres.2020.106311","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T14:28:39Z","timestamp":1579876119000},"page":"106311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Outcome of elderly patients with classical Hodgkin\u2019s lymphoma"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-6250","authenticated-orcid":false,"given":"A.","family":"Sykorova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Mocikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lukasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Stepankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Prochazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Belada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Klaskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gaherova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chroust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Buresova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2020.106311_bib0005","first-page":"1369","article-title":"Hodgkin lymphoma in older patients: an uncommon disease in need of study","volume":"22","author":"Evens","year":"2008","journal-title":"Oncology (Williston Park, N.Y.)"},{"issue":"6","key":"10.1016\/j.leukres.2020.106311_bib0010","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.12722","article-title":"Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century","volume":"164","author":"Pulte","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2020.106311_bib0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CCO.0b013e328348c6c1","article-title":"How we treat elderly patients with Hodgkin lymphoma","volume":"23","author":"Bj\u00f6rkholm","year":"2011","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106311_bib0020","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2020.106311_bib0025","first-page":"982","article-title":"Hodgkin\u2019s lymphoma in the elderly: a different disease in patients over 60","volume":"21","author":"Klimm","year":"2007","journal-title":"Oncology (Williston Park, N.Y.)"},{"issue":"Suppl 6","key":"10.1016\/j.leukres.2020.106311_bib0030","doi-asserted-by":"crossref","first-page":"vi55","DOI":"10.1093\/annonc\/mdr378","article-title":"Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Eichenauer","year":"2011","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106311_bib0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.critrevonc.2008.12.007","article-title":"Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future","volume":"71","author":"Proctor","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106311_bib0040","doi-asserted-by":"crossref","first-page":"e2014050","DOI":"10.4084\/mjhid.2014.050","article-title":"Hodgkin\u2019s Lymphoma in Older Patients: an Orphan Disease?","volume":"6","author":"Thyss","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"5","key":"10.1016\/j.leukres.2020.106311_bib0045","first-page":"450","article-title":"Results of a low aggressivity chemotherapy regimen (CVP\/CEB) in elderly Hodgkin\u2019s disease patients","volume":"81","author":"Levis","year":"1996","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.leukres.2020.106311_bib0050","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2020.106311_bib0055","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","article-title":"A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients","volume":"56","author":"Salvi","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"issue":"6","key":"10.1016\/j.leukres.2020.106311_bib0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2011-0417","article-title":"Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma","volume":"17","author":"Spina","year":"2012","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.leukres.2020.106311_bib0065","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.leukres.2020.106311_bib0070","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.leukres.2020.106311_bib0075","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2020.106311_bib0080","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2018-99-114519","article-title":"PET-guided treatment of early-stage favorable hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the german hodgkin study group","volume":"132","author":"Fuchs","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2020.106311_bib0085","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106311_bib0090","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106311_bib0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2020.106311_bib0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","author":"Evens","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2020.106311_bib0105","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2018-99-119363","article-title":"B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)","volume":"132","author":"Boell","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2020.106311_bib0110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V130.Suppl_1.651.651","article-title":"Nivolumab for newly diagnosed advanced-stage classical hodgkin lymphoma (cHL): results from the phase 2 checkmate 205 study","volume":"130","author":"Ramchandren","year":"2017","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2020.106311_bib0115","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106311_bib0120","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106311_bib0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106311_bib0130","first-page":"5","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106311_bib0135","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2020.106311_bib0140","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2009-11-253211","article-title":"Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"116","author":"Halbsguth","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2020.106311_bib0145","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2020.106311_bib0150","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2020.106311_bib0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106311_bib0160","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106311_bib0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study","volume":"15","author":"Levis","year":"2004","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2020.106311_bib0170","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2020.106311_bib0175","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin\u2019s lymphoma","volume":"48","author":"Kolstad","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"25","key":"10.1016\/j.leukres.2020.106311_bib0180","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2020.106311_bib0185","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.13904","article-title":"Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)","volume":"172","author":"Zallio","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2020.106311_bib0190","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/10428190290033332","article-title":"Treatment of elderly Hodgkin\u2019s lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study","volume":"43","author":"Macpherson","year":"2002","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2020.106311_bib0195","first-page":"46","article-title":"Probability of cure in elderly Hodgkin\u2019s disease patients","volume":"79","author":"Levis","year":"1994","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2020.106311_bib0200","first-page":"1087","article-title":"Hodgkin\u2019s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2020.106311_bib0205","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.1989.tb00268.x","article-title":"Hodgkin\u2019s disease and age","volume":"43","author":"Specht","year":"1989","journal-title":"Eur. J. Haematol."},{"issue":"27","key":"10.1016\/j.leukres.2020.106311_bib0210","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2020.106311_bib0215","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N. Engl. J. Med."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:31Z","timestamp":1758934831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620300163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":43,"alternative-id":["S0145212620300163"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106311","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of elderly patients with classical Hodgkin\u2019s lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106311"}}